HIMSS: Insite One tests the interoperability limits

ATLANTA—In addition to demonstrating new InDex enterprise archive service features, InSite One also featured one of its actor/roles profiles from the 2010 North America IHE Connectathon at the Interoperability Showcase during HIMSS10 this week.

The Wallingford, Conn.-based company featured an expanded toolset using the enterprise archive as a conduit for patient health information exchange. InDex's enterprise archive services enable institutions and affiliated clinical partners to share patient data while leveraging a common data management service. The InDex enterprise archive service, an IHE standards-based archive, continues to expand beyond two petabytes of clinical data, the company said.

At the 2010 North America IHE Connectathon, held in January in Chicago, InSite One tested its Document Source/Document Consumer actors for the Cross-Enterprise Clinical Documents Share (XDS.b) profile as well as the Imaging Document Source/Imaging Document Consumer actors for the new Cross-Enterprise Document Sharing for Imaging (XDS-I.b) profile.

The systems integration testing took place with more than 20 health IT suppliers, InSite One said.

“The fact that InSite One successfully tested the new XDS-I.b standard demonstrates its impact IHE has on interoperability,” said Robert Porper, senior vice president of product development at InSite One. “Many of InSite One’s tests during this effort required standards-based integration of four disparate systems from four different organizations.”

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.